ResMed's Q4 2026 Earnings: Wall Street Expectations and Market Impact

San Diego-based ResMed Inc. (RMD), a global health technology company specializing in AI-powered digital health solutions and cloud-connected devices, is under scrutiny for its upcoming fiscal Q4 2026 results. With a $29.9 billion market cap and operations in over 140 countries, the firm is expanding home healthcare through personalized sleep and respiratory care. In Q3 2026, it delivered 11% YoY revenue growth and $2.86 adjusted EPS, surpassing estimates but facing a 4.1% stock decline.

ResMed's GLP-1-Driven Sleep Apnea Market Expansion

■Analysts project Q4 2026 adjusted EPS of $2.90, up 13.7% YoY.

■Full-year 2026 adjusted EPS forecast stands at $11.13, reflecting a 16.5% YoY increase.

■GLP-1 weight-loss drugs may expand the sleep apnea treatment pool via heightened awareness.

Market Dynamics and Risk Assessment

■RMD shares have fallen 18.7% over 52 weeks, trailing S&P 500 (+19.8%) and XLV (+20.2%).

■Analysts maintain a 'Moderate Buy' stance, with an average price target of $246.64, implying 18.9% upside.

Ege Kaan: ResMed's trajectory underscores evolving healthcare demand. Integration of GLP-1 therapies with its devices could drive long-term revenue growth, but near-term volatility remains tied to earnings surprises. Watch for VIX trends and gamma squeeze signals in options markets, as FDA approvals and treatment accessibility reshape the investment narrative.